Conference report: Dhara - Vision Ayurveda 2047

The Dhara-Ayurveda 2047 conference was organized at the University of Trans-Disciplinary Health Sciences and Technology (TDU), Bengaluru on 23rd and September 24, 2022. This was a pioneering initiative of Ministry of Culture and Ministry of Ayush to raise public awareness about the contemporary relevance of India's medical heritage. The theme of the conference was to offer innovative approaches to strengthen and globalize Ayurveda by the year 2047 to commemorate 100th year of independence of India.More than 2000 delegates from academia and industries attended this event. This conference featured a range of components including insightful vision talks, educational exhibition, interactive practical sessions, innovation-focused competition, cultural programs, and health assessment program. Distinguished speakers shared their forward-looking perspectives on the future of Ayurveda in the year 2047 with respect to personalized nutrition, Ayurvedic healthcare, interdisciplinary medicine, AYUSH integration, Ayurvedic industry, and other related topics. The conference provided a platform for students to learn innovative approaches in Ayurveda and also awarded deserving winners for their ideas.Thus, Dhara-Ayurveda 2047 conference served as a valuable platform for sharing knowledge and exploring the future of Ayurveda in India across different disciplines related to Ayurveda like biomedical sciences and engineering, information technology, pharmaceutical sciences and folk healers to visualize Ayurveda in the year 2047

Ayurveda botanicals in COVID-19 management: An in silico multi-target approach.

The Coronavirus disease (COVID-19) caused by the virus SARS-CoV-2 has become a global pandemic in a very short time span. Currently, there is no specific treatment or vaccine to counter this highly contagious disease. There is an urgent need to find a specific cure for the disease and global efforts are directed at developing SARS-CoV-2 specific antivirals and immunomodulators. Ayurvedic Rasayana therapy has been traditionally used in India for its immunomodulatory and adaptogenic effects, and more recently has been included as therapeutic adjuvant for several maladies. Amongst several others, Withania somnifera (Ashwagandha), Tinospora cordifolia (Guduchi) and Asparagus racemosus (Shatavari) play an important role in Rasayana therapy. The objective of this study was to explore the immunomodulatory and anti SARS-CoV2 potential of phytoconstituents from Ashwagandha, Guduchi and Shatavari using network pharmacology and docking. The plant extracts were prepared as per ayurvedic procedures and a total of 31 phytoconstituents were identified using UHPLC-PDA and mass spectrometry studies. To assess the immunomodulatory potential of these phytoconstituents an in-silico network pharmacology model was constructed. The model predicts that the phytoconstituents possess the potential to modulate several targets in immune pathways potentially providing a protective role. To explore if these phytoconstituents also possess antiviral activity, docking was performed with the Spike protein, Main Protease and RNA dependent RNA polymerase of the virus. Interestingly, several phytoconstituents are predicted to possess good affinity for the three targets, suggesting their application for the termination of viral life cycle. Further, predictive tools indicate that there would not be adverse herb-drug pharmacokinetic-pharmacodynamic interactions with concomitantly administered drug therapy. We thus make a compelling case to evaluate the potential of these Rasayana botanicals as therapeutic adjuvants in the management of COVID-19 following rigorous experimental validation